A Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Phase 2 Study of Efficacy and Safety of Tirzepatide in Individuals with Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease
The National Institutes of Health (NIH) is conducting a research study to explore whether an investigational GLP1 medication called Tirzepatide can help people improve liver health. This study focuses on individuals who are overweight and drink alcohol regularly.
NIAAA Natural History Protocol
To look at a broad range of traits in people who are healthy people and people with alcohol problems. To study them for potential eligibility for other research protocols conducted at the NIH Clinical Center.
Taste and Smell Differences in Obese Versus Non-Obese Individuals
Nicotinic Receptor Genetic Variation and Alcohol Reward
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction